Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ)
Yantai, JS, CN
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.75% | +0.63% | -3.98% | -3.83% | -16.13% | -6.91% | -12.46% | -21.49% | -38.80% | +2.08% | +135.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-5.1% Q1'26: -8.8% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+7.7% Q1'26: +35.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+8.2% Q1'26: -16.7% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+12.9% ★ Q1'26: +13.3% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+3.7% Q1'26: +4.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×4.56× Q1'26: 3.50× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
794.92M
est: 795.00M (0.0%)
|
1.16B
est: 1.14B (+1.5%)
|
1.60B
est: 1.43B (+11.7%)
|
2.33B
est: 1.77B (+31.9%)
|
3.42B
est: 3.64B (-6.0%)
|
3.91B
est: 3.77B (+3.8%)
|
3.58B
est: 4.14B (-13.4%)
|
3.28B
est: 3.32B (-1.4%)
|
2.87B
est: 2.89B (-0.6%)
|
2.72B
est: 2.85B (-4.5%)
|
2.99B
2.96B – 3.01B
+4.9% YoY
|
3.23B
3.18B – 3.29B
+8.2% YoY
|
3.52B
3.48B – 3.57B
+8.9% YoY
|
| EBITDA |
148.52M
est: 142.08M (+4.5%)
|
262.51M
est: 203.91M (+28.7%)
|
415.67M
est: 255.38M (+62.8%)
|
586.92M
est: 316.14M (+85.6%)
|
727.85M
est: 650.07M (+12.0%)
|
727.92M
est: 673.57M (+8.1%)
|
672.09M
est: 739.51M (-9.1%)
|
511.69M
est: 593.86M (-13.8%)
|
432.69M
est: 624.37M (-30.7%)
|
572.16M
est: 616.63M (-7.2%)
|
646.57M
640.98M – 652.16M
+4.9% YoY
|
699.36M
687.44M – 711.29M
+8.2% YoY
|
761.95M
751.99M – 771.91M
+8.9% YoY
|
| EBIT |
114.07M
est: 112.27M (+1.6%)
|
218.56M
est: 161.14M (+35.6%)
|
359.42M
est: 201.81M (+78.1%)
|
506.44M
est: 249.83M (+102.7%)
|
625.11M
est: 513.70M (+21.7%)
|
612.99M
est: 532.28M (+15.2%)
|
551.72M
est: 584.39M (-5.6%)
|
373.77M
est: 469.29M (-20.4%)
|
282.61M
est: 376.69M (-25.0%)
|
352.30M
est: 372.01M (-5.3%)
|
390.08M
386.70M – 393.45M
+4.9% YoY
|
421.93M
414.73M – 429.12M
+8.2% YoY
|
459.69M
453.68M – 465.69M
+8.9% YoY
|
| Net Income |
89.75M
est: 112.70M (-20.4%)
|
130.95M
est: 230.89M (-43.3%)
|
172.63M
est: 299.60M (-42.4%)
|
280.43M
est: 313.35M (-10.5%)
|
417.77M
est: 437.04M (-4.4%)
|
151.56M
est: 276.24M (-45.1%)
|
307.29M
est: 387.56M (-20.7%)
|
209.74M
est: 404.05M (-48.1%)
|
183.83M
est: 189.66M (-3.1%)
|
195.63M
est: 280.36M (-30.2%)
|
286.55M
281.68M – 291.41M
+2.2% YoY
|
350.45M
344.50M – 356.41M
+22.3% YoY
|
408.17M
401.24M – 415.11M
+16.5% YoY
|
| SGA |
171.67M
est: 183.81M (-6.6%)
|
301.06M
est: 263.81M (+14.1%)
|
433.17M
est: 330.39M (+31.1%)
|
706.79M
est: 409.00M (+72.8%)
|
878.23M
est: 841.01M (+4.4%)
|
795.18M
est: 871.42M (-8.7%)
|
777.75M
est: 956.73M (-18.7%)
|
747.89M
est: 768.30M (-2.7%)
|
718.70M
est: 671.83M (+7.0%)
|
721.28M
est: 663.50M (+8.7%)
|
695.72M
689.70M – 701.73M
+4.9% YoY
|
752.52M
739.69M – 765.36M
+8.2% YoY
|
819.87M
809.15M – 830.58M
+8.9% YoY
|
| EPS |
0.14
est: 0.14 (+2.4%)
|
0.20
est: 0.28 (-29.7%)
|
0.25
est: 0.36 (-32.5%)
|
0.37
est: 0.38 (-2.6%)
|
0.52
est: 0.53 (-1.9%)
|
0.19
est: 0.34 (-43.6%)
|
0.38
est: 0.47 (-19.1%)
|
0.25
est: 0.49 (-48.1%)
|
0.22
est: 0.23 (-3.1%)
|
0.24
est: 0.34 (-29.4%)
|
0.35
0.34 – 0.35
+2.2% YoY
|
0.43
0.42 – 0.43
+22.3% YoY
|
0.50
0.49 – 0.50
+16.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.02% | 106.0K | 0.59% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 59.3K | 0.49% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 1.81M | 0.07% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 393.4K | 0.06% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 100.6K | 0.39% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 12.9K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 29.2K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.44M | 0.06% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 34.8K | 0.10% |
| 10 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 3.0K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao Wang | Accounting Supervisor | — | — |
| Chun Ping Zhu | Chief Financial Officer | — | female |
| Chun Xiang Lu | Deputy General Manager | — | male |
| Jing Sun | Deputy General Manager | — | female |
| Sai You | Deputy GM & Non-Independent Director | — | female |
| Xiao Jie Liu | Deputy GM, Board Secretary & Director | — | male |
| Xiaoming Wu | Deputy General Manager | — | male |
| Zhi Gang Luo | GM & Non-Independent Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002675.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
